Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial

被引:0
作者
Franco-Moreno, Anabel [1 ]
Acedo-Gutierrez, Maria Soledad [1 ]
Casado-Suela, Miguel angel [1 ]
Martin, Nicolas Labrador-San [1 ]
de Carranza-Lopez, Maria [1 ]
Ibanez-Estellez, Fatima [2 ]
Hernandez-Blanco, Clara [3 ]
Jimenez-Torres, Jose [4 ]
Vallejo-Maroto, Ignacio [4 ]
Romero-Pareja, Rodolfo [5 ,6 ]
Pena-Lillo, Gabriela [7 ]
Escobar-Rodriguez, Ismael [8 ]
Torres-Macho, Juan [1 ,9 ]
机构
[1] Hosp Univ Infanta Leonor Virgen Torre, Internal Med Dept, Madrid, Spain
[2] Hosp Univ Puerta Hierro, Internal Med Dept, Madrid, Spain
[3] Hosp Carlos III, Internal Med Dept, Madrid, Spain
[4] Hosp Emergencia COVID 19, Seville, Spain
[5] Hosp Emergencias Enfermera Isabel Zendal, Madrid, Spain
[6] European Univ, Madrid, Spain
[7] Hosp Univ Infanta Leonor Virgen Torre, Emergency Dept, Madrid, Spain
[8] Hosp Univ Infanta Leonor Virgen Torre, Pharmacol Dept, Madrid, Spain
[9] Univ Complutense, Dept Med, Madrid, Spain
关键词
acute respiratory distress syndrome; biomarkers; COVID-19; management; dexamethasone; inflammation; mortality; pneumonia; randomized controlled trial;
D O I
10.3389/fmed.2024.1385833
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives Corticosteroids are among the drugs demonstrating a mortality benefit for coronavirus disease 2019 (COVID-19). The RECOVERY trial highlighted that dexamethasone reduced 28-day mortality for hospitalized COVID-19 patients requiring either supplemental oxygen or mechanical ventilation. It is noted that approximately 30% of COVID-19 patients, initially presenting with mild symptoms, will advance to acute respiratory distress syndrome (ARDS), especially those with detectable laboratory markers of inflammation indicative of disease progression. Our research aimed to explore the efficacy of dexamethasone in preventing the progression to ARDS in patients hospitalized with COVID-19 pneumonia who do not yet require additional oxygen but are at high risk of developing ARDS, potentially leading to a reduction in morbimortality.Methods In this multicenter, randomized, controlled trial, we evaluated the impact of dexamethasone on adult patients diagnosed with COVID-19 pneumonia who did not need supplementary oxygen at admission but were identified as having risk factors for ARDS. The risk of ARDS was determined based on specific criteria: elevated lactate dehydrogenase levels over 245 U/L, C-reactive protein levels exceeding 100 mg/L, and a lymphocyte count below 0.80 x 109/L. Participants were randomly allocated to either receive dexamethasone or the standard care. The primary endpoints included the incidence of moderate or severe ARDS and all-cause mortality within 30 days post-enrollment.Results One hundred twenty-six patients were randomized. Among them, 41 were female (30.8%), with a mean age of 48.8 +/- 14.4 years. Ten patients in the dexamethasone group (17.2%) and ten patients in the control group (14.7%) developed moderate ARDS with no significant differences. Mechanical ventilation was required in six patients (4.7%), with four in the treatment group and two in the control group. There were no deaths during hospitalization or during follow-up. An intermediate analysis for futility showed some differences between the control and treatment groups (Z = 0.0284). However, these findings were within the margins close to the region where the null hypothesis would not be rejected.Conclusion In patients with COVID-19 pneumonia without oxygen needs but at risk of progressing to severe disease, early dexamethasone administration did not lead to a decrease in ARDS development.Clinical trial registration ClinicalTrials.gov, identifier NCT04836780.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19 [J].
Incognito, Anthony, V ;
Millar, Philip J. ;
Pyle, W. Glen .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2021, 320 (03) :L331-L338
[42]   Effect of pulsed corticosteroids and tocilizumab on hyperinflammation in COVID-19 patients with acute respiratory distress syndrome [J].
Aslan, Murat ;
Sabaz, Mehmet Suleyman ;
Yilmaz, Rabia ;
Asar, Sinan ;
Seker, Yasemin Tekdos ;
Hergunsel, Gulsum Oya .
JOURNAL OF ACUTE DISEASE, 2021, 10 (05) :195-201
[43]   Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial [J].
Jesús Villar ;
José M. Añón ;
Carlos Ferrando ;
Gerardo Aguilar ;
Tomás Muñoz ;
José Ferreres ;
Alfonso Ambrós ;
César Aldecoa ;
Fernando Suárez-Sipmann ;
Kevin E. Thorpe ;
Peter Jüni ;
Arthur S. Slutsky .
Trials, 21
[44]   Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial) [J].
Gorman, Ellen A. ;
Rynne, Jennifer ;
Gardiner, Hannah J. ;
Rostron, Anthony J. ;
Bannard-Smith, Jonathan ;
Bentley, Andrew M. ;
Brealey, David ;
Campbell, Christina ;
Curley, Gerard ;
Clarke, Mike ;
Dushianthan, Ahilanadan ;
Hopkins, Phillip ;
Jackson, Colette ;
Kefela, Kallirroi ;
Krasnodembskaya, Anna ;
Laffey, John G. ;
McDowell, Cliona ;
McFarland, Margaret ;
McFerran, Jamie ;
McGuigan, Peter ;
Perkins, Gavin D. ;
Silversides, Jonathan ;
Smythe, Jon ;
Thompson, Jacqui ;
Tunnicliffe, William S. ;
Welters, Ingeborg D. M. ;
Amado-Rodriguez, Laura ;
Albaiceta, Guillermo ;
Williams, Barry ;
Shankar-Hari, Manu ;
McAuley, Daniel F. ;
O'Kane, Cecilia M. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (03) :256-269
[45]   Impact of Methylprednisolone Pulse on the Mortality of Patients With Acute Respiratory Distress Syndrome Secondary to COVID-19 [J].
Sousa, Adrian ;
Lima, Olalla ;
Perez-Gonzalez, Alexandre ;
Araujo, Alejandro ;
Longueira, Rebeca ;
Otero, Anton ;
Nunez, Marta ;
Ramos, Cristina ;
Martinez-Lamas, Lucia ;
Crespo-Casal, Manuel ;
Rubianes, Martin ;
Perez-Rodriguez, Maria Teresa .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2023, 31 (06)
[46]   Acute Hypoxemic Respiratory Failure in Children at the Start of COVID-19 Outbreak: A Nationwide Experience [J].
Lopez-Fernandez, Yolanda M. ;
Martinez-de-Azagra, Amelia ;
Gonzalez-Gomez, Jose M. ;
Perez-Caballero Macarron, Cesar ;
Garcia-Gonzalez, Maria ;
Parrilla-Parrilla, Julio ;
Minambres-Rodriguez, Maria ;
Madurga-Revilla, Paula ;
Gomez-Zamora, Ana ;
Rodriguez-Campoy, Patricia ;
Mayordomo-Colunga, Juan ;
Butragueno-Laiseca, Laura ;
Nunez-Borrero, Rocio ;
Gonzalez-Martin, Jesus M. ;
Slutsky, Arthur S. ;
Villar, Jesus .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
[47]   Segmental Lung Recruitment in Patients with Bilateral COVID-19 Pneumonia Complicated by Acute Respiratory Distress Syndrome: A Case Report [J].
Protic, Alen ;
Bura, Matej ;
Sustic, Alan ;
Brusic, Josip ;
Sotosek, Vlatka .
MEDICINA-LITHUANIA, 2023, 59 (01)
[48]   Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19 [J].
Florent Laverdure ;
Amélie Delaporte ;
Astrid Bouteau ;
Thibaut Genty ;
François Decailliot ;
François Stéphan .
Critical Care, 24
[49]   Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19 [J].
Laverdure, Florent ;
Delaporte, Amelie ;
Bouteau, Astrid ;
Genty, Thibaut ;
Decailliot, Francois ;
Stephan, Francois .
CRITICAL CARE, 2020, 24 (01)
[50]   Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis [J].
Alenezi, Faraj K. ;
Almeshari, Mohammed A. ;
Mahida, Rahul ;
Bangash, Mansoor N. ;
Thickett, David R. ;
Patel, Jaimin M. .
RENAL FAILURE, 2021, 43 (01) :1621-1633